Article

Sanofi to Double Flu-Vaccine Production

Sanofi Pasteur (Lyon, France, www.sanofipasteur.com), the vaccine arm of Paris-based Sanofi Aventis, recently completed construction of its new influenza vaccine manufacturing facility.

Sanofi Pasteur (Lyon, France, www.sanofipasteur.com), the vaccine arm of Paris-based Sanofi Aventis, recently completed construction of its new influenza vaccine manufacturing facility. According to the company, this manufacturing plant will more than double its production capacity in the US. The new 14,000-square-foot facility, which cost $150 million to build, is expected to start functioning in late 2008 or early 2009, after the FDA licenses the facility.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
How the 15% US-EU Tariff Cap Affects Bio/pharma
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
© 2025 MJH Life Sciences

All rights reserved.